How Azacitidine Modifies DNA and RNA in GVHD Treatment
Azacitidine is a cytidine nucleoside analog that primarily acts as a hypomethylating agent by incorporating into DNA and RNA, disrupting nucleic acid function to modulate gene expression. In graft-versus-host disease (GVHD), it targets hyperactive donor immune cells, reducing inflammation and tissue damage through epigenetic changes.[1]
Mechanism in DNA Modification
Azacitidine enters cells via nucleoside transporters and gets converted to azacitidine triphosphate (aza-CTP). This incorporates into newly synthesized DNA during the S-phase by DNA polymerase, where it traps DNA methyltransferases (DNMTs) like DNMT1. The trapped DNMTs form covalent adducts with DNA, leading to:
- DNMT depletion and proteasomal degradation.
- Global DNA hypomethylation, reactivating silenced genes such as tumor suppressors or immunomodulatory factors (e.g., FOXP3 in Tregs).
In GVHD, this hypomethylation curbs alloreactive T-cell proliferation and effector function, promoting regulatory T cells (Tregs) and shifting donor T cells toward tolerance.[2][3]
Mechanism in RNA Modification
Aza-CTP also incorporates into RNA, including ribosomal, messenger, and transfer RNA. This causes:
- Faulty RNA processing and maturation.
- Inhibition of RNA methyltransferases.
- Disruption of polyribosome assembly, impairing protein synthesis.
These effects are dose-dependent; lower doses favor RNA incorporation (70-90%), amplifying translational stress on rapidly dividing GVHD effector cells like CD8+ T cells, leading to selective apoptosis without broad myelosuppression.[1][4]
Specific Role in GVHD Pathophysiology
GVHD arises from donor T-cell attacks on host tissues post-allogeneic transplant. Azacitidine's dual DNA/RNA actions:
- Reduce pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) via hypomethylation of cytokine loci.
- Enhance Treg stability and function, restoring immune balance.
- Show efficacy in steroid-refractory acute/chronic GVHD, with response rates of 30-60% in trials, often sustained.[5]
Preclinical models confirm it attenuates GVHD severity without weakening graft-versus-leukemia effects.[3]
Clinical Evidence and Timing
Phase II trials (e.g., NCT01804933) report overall response rates of 53% in chronic GVHD, with DNA hypomethylation correlating to T-cell exhaustion markers (PD-1, TIM-3).[6] Effects peak 4-8 weeks post-initiation (75 mg/m² subcutaneous, days 1-7 every 28 days), driven by cumulative hypomethylation cycles.
Potential Risks and Limitations
Myelosuppression occurs in 30-50% of patients, with nausea and infections common. RNA-mediated cytotoxicity can exacerbate cytopenias in frail post-transplant patients. Not FDA-approved specifically for GVHD; used off-label.[1]
Sources
[1]: DrugPatentWatch.com - Azacitidine
[2]: Garcia-Manero G, et al. Blood 2011
[3]: Atallah E, et al. Biol Blood Marrow Transplant 2018
[4]: Issa JP, et al. Cancer Res 1986
[5]: de Lima M, et al. Haematologica 2010
[6]: ClinicalTrials.gov NCT01804933